$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny

$alny Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000117867020000019 Filed on November 05, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2019 Q3
Revenue	$163.6M	$125.9M	$70.06M
YoY Change	128.18%	79.63%	3286.23%
Cost Of Revenue	$23.00M	$20.83M	$5.213M
YoY Change	88.52%	299.5%	3705.11%
Gross Profit	$140.5M	$105.0M	$64.85M
YoY Change	136.13%	61.96%	3256.52%
Gross Profit Margin	85.9%	83.45%	92.56%
Selling, General & Admin	$166.3M	$167.5M	$120.4M
YoY Change	6.4%	39.15%	3.27%
% of Gross Profit	118.36%	159.46%	185.59%
Research & Development	$168.5M	$161.8M	$160.8M
YoY Change	-16.29%	0.61%	14.9%
% of Gross Profit	119.93%	154.04%	247.96%
Depreciation & Amortization	$10.40M	$8.600M	-$10.30M
YoY Change	89.09%	-183.5%	-412.12%
% of Gross Profit	7.4%	8.19%	-15.88%
Operating Expenses	$334.8M	$329.3M	$281.1M
YoY Change	-6.38%	17.11%	9.61%
Operating Profit	-$194.3M	-$225.2M	-$216.3M
YoY Change	-34.82%	4.11%	-15.03%
Interest Expense	-$27.40M	$28.73M	$0.00
YoY Change	-475.34%		-100.0%
% of Operating Profit
Other Income/Expense, Net	-$22.00M	-$27.25M	$7.370M
YoY Change	-254.93%	-469.78%	-24.18%
Pretax Income	-$243.6M	-$252.5M	-$208.9M
YoY Change	-11.93%	20.83%	-14.67%
Income Tax	-$100.0K	$839.0K	-$394.0K
% Of Pretax Income
Net Earnings	-$243.5M	-$253.3M	-$208.5M
YoY Change	-11.82%	21.46%	-14.98%
Net Earnings / Revenue	-148.9%	-201.26%	-297.65%
Basic Earnings Per Share		-$2.18
Diluted Earnings Per Share	-$2.094M	-$2.18	-$1.918M
COMMON SHARES
Basic Shares Outstanding	116.2M shares	116.0M shares
Diluted Shares Outstanding		116.0M shares

Balance Sheet

Concept	2020 Q4	2020 Q3	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.830B	$1.777B	$1.721B
YoY Change	20.21%	3.23%	40.86%
Cash & Equivalents	$496.6M	$496.7M	$923.3M
Short-Term Investments	$1.333B	$1.280B	$797.8M
Other Short-Term Assets	$62.80M	$74.80M	$73.50M
YoY Change	-21.79%	1.77%	-19.05%
Inventory	$75.20M	$66.94M	$54.56M
Prepaid Expenses
Receivables	$102.4M	$79.12M	$48.11M
Other Receivables	$533.5M	$518.3M	$0.00
Total Short-Term Assets	$2.615B	$2.555B	$1.897B
YoY Change	52.39%	34.65%	41.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$465.0M	$444.7M	$396.5M
YoY Change	9.37%	12.17%	45.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$45.05M	$37.93M	$9.632M
YoY Change	149.29%	293.81%	-84.18%
Total Long-Term Assets	$792.3M	$752.6M	$644.4M
YoY Change	16.64%	16.8%	93.16%
TOTAL ASSETS
Total Short-Term Assets	$2.615B	$2.555B	$1.897B
Total Long-Term Assets	$792.3M	$752.6M	$644.4M
Total Assets	$3.407B	$3.307B	$2.542B
YoY Change	42.25%	30.12%	51.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$51.97M	$27.87M	$39.39M
YoY Change	4.17%	-29.24%	80.7%
Accrued Expenses	$355.9M	$295.3M	$177.9M
YoY Change	80.48%	65.92%	90.12%
Deferred Revenue	$127.2M	$114.6M	$107.4M
YoY Change	63.46%	6.75%	3017.28%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$585.3M	$480.2M	$352.9M
YoY Change	65.99%	36.1%	190.42%
LONG-TERM LIABILITIES
Long-Term Debt	$191.3M	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$37.91M	$16.34M	$9.036M
YoY Change	306.3%	80.84%	-80.36%
Total Long-Term Liabilities	$37.91M	$16.34M	$9.036M
YoY Change	306.3%	80.84%	-88.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$585.3M	$480.2M	$352.9M
Total Long-Term Liabilities	$37.91M	$16.34M	$9.036M
Total Liabilities	$2.391B	$2.092B	$934.5M
YoY Change	149.97%	123.88%	373.18%
SHAREHOLDERS EQUITY
Retained Earnings	-$4.585B	-$4.342B	-$3.451B
YoY Change	23.03%	25.82%
Common Stock	$5.645B	$5.594B	$5.092B
YoY Change	8.51%	9.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.016B	$1.215B	$1.607B
YoY Change
Total Liabilities & Shareholders Equity	$3.407B	$3.307B	$2.542B
YoY Change	42.25%	30.12%	51.68%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2019 Q3
OPERATING ACTIVITIES
Net Income	-$243.5M	-$253.3M	-$208.5M
YoY Change	-11.82%	21.46%	-14.98%
Depreciation, Depletion And Amortization	$10.40M	$8.600M	-$10.30M
YoY Change	89.09%	-183.5%	-412.12%
Cash From Operating Activities	-$123.2M	-$110.3M	-$182.6M
YoY Change	-37.14%	-39.59%	18.73%
INVESTING ACTIVITIES
Capital Expenditures	-$21.70M	-$12.40M	-$36.10M
YoY Change	-44.07%	-65.65%	-20.48%
Acquisitions
YoY Change
Other Investing Activities	-$76.30M	$2.400M	$26.00M
YoY Change	-58.08%	-90.77%	-81.64%
Cash From Investing Activities	-$97.90M	-$10.10M	-$10.00M
YoY Change	-55.68%	1.0%	-110.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	218.0M	34.10M	-20.70M
YoY Change	439.6%	-264.73%	-259.23%
NET CHANGE
Cash From Operating Activities	-123.2M	-110.3M	-182.6M
Cash From Investing Activities	-97.90M	-10.10M	-10.00M
Cash From Financing Activities	218.0M	34.10M	-20.70M
Net Change In Cash	-3.100M	-86.30M	-213.3M
YoY Change	-99.18%	-59.54%	378.25%
FREE CASH FLOW
Cash From Operating Activities	-$123.2M	-$110.3M	-$182.6M
Capital Expenditures	-$21.70M	-$12.40M	-$36.10M
Free Cash Flow	-$101.5M	-$97.90M	-$146.5M
YoY Change	-35.43%	-33.17%	35.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001178670
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36407
	dei	Entity Registrant Name EntityRegistrantName	ALNYLAM PHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0602661
	dei	Entity Address Address Line1 EntityAddressAddressLine1	675 West Kendall Street,
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Henri A. Termeer Square
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
	dei	City Area Code CityAreaCode	617
	dei	Local Phone Number LocalPhoneNumber	551-8200
	dei	Local Phone Number LocalPhoneNumber	551-8200
	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
	dei	Trading Symbol TradingSymbol	ALNY
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	116180768	shares
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	496704000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	547178000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1279955000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	975017000	USD
CY2020Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	57217000	USD
CY2019Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	13967000	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	79118000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	43011000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	66942000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	56348000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	74766000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	80343000	USD
CY2020Q3	alny	Royalties Receivable Current RoyaltiesReceivableCurrent	500000000	USD
CY2019Q4	alny	Royalties Receivable Current RoyaltiesReceivableCurrent	0	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	2554702000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	1715864000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	444690000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	425179000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18069000	USD
CY2020Q3	us-gaap	Assets Assets	3307283000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	245234000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	221197000	USD
CY2020Q3	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	24725000	USD
CY2019Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	14825000	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	37932000	USD
CY2019Q4	us-gaap	Assets Assets	2395134000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	27872000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	49884000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	295260000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	197201000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	32192000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	27688000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	114601000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	77821000	USD
CY2020Q3	alny	Royalty Liability Current RoyaltyLiabilityCurrent	10316000	USD
CY2019Q4	alny	Royalty Liability Current RoyaltyLiabilityCurrent	0	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	480241000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	352594000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	297262000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	276135000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	265708000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	318383000	USD
CY2020Q3	alny	Royalty Liability Noncurrent RoyaltyLiabilityNoncurrent	1032708000	USD
CY2019Q4	alny	Royalty Liability Noncurrent RoyaltyLiabilityNoncurrent	0	USD
CY2020Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16341000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9330000	USD
CY2020Q3	us-gaap	Liabilities Liabilities	2092260000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	956442000	USD
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	116143000	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	116143000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	112188000	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	112188000	shares
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	1161000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	1122000	USD
CY2020Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	5592884000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	5201176000	USD
CY2020Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-37193000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-36518000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4341829000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3727088000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	1215023000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1438692000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3307283000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2395134000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	125853000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	70061000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	329291000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	148069000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	21797000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5213000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	55028000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	12886000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	161783000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	160796000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	486350000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	453813000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	167472000	USD
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	120351000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	422129000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	322728000	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	351052000	USD
CY2019Q3	us-gaap	Costs And Expenses CostsAndExpenses	286360000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	963507000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	789427000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-225199000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-216299000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-634216000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-641358000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	28731000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	55979000	USD
	us-gaap	Interest Expense InterestExpense	0	USD
CY2020Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2072000	USD
CY2019Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	9889000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	10717000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	26195000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-594000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2519000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	67477000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2929000	USD
CY2020Q3	alny	Change In Fair Value Of Liability Obligation ChangeInFairValueOfLiabilityObligation	0	USD
CY2019Q3	alny	Change In Fair Value Of Liability Obligation ChangeInFairValueOfLiabilityObligation	0	USD
	alny	Change In Fair Value Of Liability Obligation ChangeInFairValueOfLiabilityObligation	0	USD
	alny	Change In Fair Value Of Liability Obligation ChangeInFairValueOfLiabilityObligation	9422000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-27253000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7370000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	22215000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	32688000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-252452000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-208929000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-612001000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-608670000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	839000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-394000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2740000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1261000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-253291000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-208535000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-614741000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-609931000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.18
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.92
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.37
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.63
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	115986000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	108701000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	114554000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	108427000	shares
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-253291000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-208535000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-614741000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	2281000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-76000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-71000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-609931000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1481000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-50000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	768000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	772000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-2576000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1439000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1665000	USD
	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-222000	USD
	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	4211000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3981000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1460000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-675000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1158000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-257272000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-207075000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-615416000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-611089000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1438692000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	54221000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	0	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	34578000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	4459000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-182221000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	1349729000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	91873000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	5301000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	99498000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	33707000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1153000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	381900000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32541000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	360000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-179229000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	1399726000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	32212000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	129000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	40228000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3981000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-253291000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	1215023000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1301965000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11409000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	-58000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	784000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-181915000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	1546986000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6182000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	4022000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	1089000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	390577000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	30798000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2978000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-219481000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	1757195000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9300000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	0	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	1002000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	46665000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1460000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-208535000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	1607087000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-614741000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-609931000	USD
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	24386000	USD
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	11733000	USD
	alny	Amortization And Interest Accretion Related To Operating Leases AmortizationAndInterestAccretionRelatedToOperatingLeases	29169000	USD
	alny	Amortization And Interest Accretion Related To Operating Leases AmortizationAndInterestAccretionRelatedToOperatingLeases	27873000	USD
	alny	Non Cash Interest Expense On Sale Of Future Royalties NonCashInterestExpenseOnSaleOfFutureRoyalties	55979000	USD
	alny	Non Cash Interest Expense On Sale Of Future Royalties NonCashInterestExpenseOnSaleOfFutureRoyalties	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	105597000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	108644000	USD
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	66626000	USD
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	0	USD
	alny	Change In Fair Value Of Liability Obligation ChangeInFairValueOfLiabilityObligation	0	USD
	alny	Change In Fair Value Of Liability Obligation ChangeInFairValueOfLiabilityObligation	9422000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	1628000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-2061000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	35070000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	29717000	USD
	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	-2690000	USD
	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	-29064000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	26962000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	28095000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3765000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	12748000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	75564000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	57368000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-15924000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	399584000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	31272000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	24739000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-491817000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-82447000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	48693000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	101351000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1469451000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	99498000	USD
	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	0	USD
	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-337630000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-196827000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	181459000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	30942000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1445632000	USD
	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	9900000	USD
	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	30000000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1190714000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1320156000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	300000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	USD
	alny	Proceeds From Sale Of Royalties Interest ProceedsFromSaleOfRoyaltiesInterest	500000000	USD
	alny	Proceeds From Sale Of Royalties Interest ProceedsFromSaleOfRoyaltiesInterest	0	USD
	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	4200000	USD
	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	30000000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	381900000	USD
	alny	Payments For Transaction Costs Related To Sale Of Future Royalties And Debt PaymentsForTransactionCostsRelatedToSaleOfFutureRoyaltiesAndDebt	8128000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	400000000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	alny	Payments For Transaction Costs Related To Sale Of Future Royalties And Debt PaymentsForTransactionCostsRelatedToSaleOfFutureRoyaltiesAndDebt	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	777029000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	782842000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1946000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-449000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-50472000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	503119000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	549628000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	422631000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	499156000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	925750000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	7048000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	18923000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	34363000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2546000	USD
	alny	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	500000000	USD
	alny	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	0	USD
	us-gaap	Nature Of Operations NatureOfOperations	NATURE OF BUSINESS<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, we, our or us) commenced operations on June 14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on RNA interference, or RNAi. We are committed to the advancement of our company strategy of building a multi-product, global, commercial biopharmaceutical company with a deep and sustainable clinical pipeline of RNAi therapeutics for future growth and a robust, organic research engine for sustainable innovation and great potential for patient impact. Since inception, we have focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic alliances with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic partners. We have devoted substantially all of our efforts to business planning, research, development, manufacturing and early commercial efforts, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2018, we received approval for ONPATTRO from the United States Food and Drug Administration, or FDA, and began commercializing and generating product revenues in the U.S., and also received marketing authorization for ONPATTRO from the European Commission, or EC. As of September 30, 2020, we have launched ONPATTRO in the U.S., Europe, Japan and in several additional countries. In November 2019, we received approval for GIVLAARI from the FDA and began commercializing and generating product revenues in the U.S. in December 2019. In March 2020, we received marketing authorization for GIVLAARI from the EC, and as of September 30, 2020, we have launched GIVLAARI in several countries in Europe. Regulatory filings in additional markets are pending or planned for the remainder of 2020 and beyond for both products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2020, we entered into a broad strategic financing collaboration with The Blackstone Group Inc. and certain of its affiliates which includes a purchase and sale agreement, a credit agreement, a stock purchase agreement, and a funding agreement for the clinical development of vutrisiran and ALN-AGT, under which The Blackstone Group Inc. and certain of its affiliates will provide up to $2.00 billion to support our advancement of innovative RNAi therapeutics. Each executed agreement is a separate unit of account and was recorded at fair value. Please read Note 5, Note 9, Note 10 and Note 11, respectively, for additional information regarding each executed agreement set forth above.</span></div>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Reclassification</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain prior period amounts in the condensed consolidated financial statements have been reclassified to conform to the current period presentation.</span></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The full extent to which the COVID-19 </span></div>pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, the supply of our products and product candidates, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.
CY2020Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	145692000	USD
CY2020Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	18331000	USD
CY2019Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	14929000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	153117000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	19212000	USD
CY2019Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	12333000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	50716000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	3954000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1294050000	USD
	alny	Fair Value Assets Level2 To Level1 Transfers Number FairValueAssetsLevel2ToLevel1TransfersNumber	1	asset
	alny	Impairment Of Marketable Debt Securities ImpairmentOfMarketableDebtSecurities	0	USD
CY2020Q3	alny	Impairment Of Marketable Debt Securities ImpairmentOfMarketableDebtSecurities	0	USD
CY2019Q3	alny	Impairment Of Marketable Debt Securities ImpairmentOfMarketableDebtSecurities	0	USD
	alny	Impairment Of Marketable Debt Securities ImpairmentOfMarketableDebtSecurities	0	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1205000	USD
CY2020Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	300000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1294955000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1315012000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	246000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	109000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1315149000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	15000000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	340132000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1279955000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	975017000	USD
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1294955000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1315149000	USD
CY2020Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	54354000	USD
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	15418000	USD
CY2020Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	22425000	USD
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	38275000	USD
CY2020Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7261000	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2655000	USD
CY2020Q3	alny	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	84040000	USD
CY2019Q4	alny	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	56348000	USD
CY2020Q3	alny	Capitalized Inventory CapitalizedInventory	19200000	USD
CY2019Q4	alny	Capitalized Inventory CapitalizedInventory	0	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	496704000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	923304000	USD
CY2020Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	5000	USD
CY2019Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	4000	USD
CY2020Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2447000	USD
CY2019Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2442000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	499156000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	925750000	USD
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-1658000	USD
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-983000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-675000	USD
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-1642000	USD
CY2019Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5000000	shares
CY2019Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	77.50
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-484000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1158000	USD
CY2020Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.17
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	381900000	USD
CY2019Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5600000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	37264000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	46009000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	105597000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	108644000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13001000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14343000	shares

Files In Submission

Name	View Source	Status
0001178670-20-000019-index-headers.html	Edgar Link	pending
0001178670-20-000019-index.html	Edgar Link	pending
0001178670-20-000019.txt	Edgar Link	pending
0001178670-20-000019-xbrl.zip	Edgar Link	pending
alny-20200930.htm	Edgar Link	pending
alny-20200930.xsd	Edgar Link	pending
alny-20200930_cal.xml	Edgar Link	unprocessable
alny-20200930_def.xml	Edgar Link	unprocessable
alny-20200930_g1.jpg	Edgar Link	pending
alny-20200930_g2.jpg	Edgar Link	pending
alny-20200930_htm.xml	Edgar Link	completed
alny-20200930_lab.xml	Edgar Link	unprocessable
alny-20200930_pre.xml	Edgar Link	unprocessable
alny2020q310-qex101.htm	Edgar Link	pending
alny2020q310-qex103.htm	Edgar Link	pending
alny2020q310-qex311.htm	Edgar Link	pending
alny2020q310-qex312.htm	Edgar Link	pending
alny2020q310-qex321.htm	Edgar Link	pending
alny2020q310-qex322.htm	Edgar Link	pending
alny2020q310-qexhibit102.htm	Edgar Link	pending
alny2020q310-qexhibit104.htm	Edgar Link	pending
alny2020q310-qexhibit31.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_01.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny

2020 Q4 Form 10-Q Financial Statement

#000117867020000019 Filed on November 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALNY ALNYLAM PHARMACEUTICALS, INC. Stock $alny

2020 Q4 Form 10-Q Financial Statement

#000117867020000019 Filed on November 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny